FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis

Oncotarget

Volumn 6, Issue 5, 2015, Pages 3409-3419

  Waters, Catherine E ^a,b   Saldivar, Joshua C ^c   Amin, Zaynab A ^b   Schrock, Morgan S ^a,b   Huebner, Kay ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

APOBEC deaminase; DNA double strand breaks; FHIT; Mutations; Replication stress

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3B; DNA; FRAGILE HISTIDINE TRIAD PROTEIN; HYDROLASE; MESSENGER RNA; PROTEIN P53; THYMIDINE; UNCLASSIFIED DRUG; ACID ANHYDRIDE HYDROLASE; APOBEC3B PROTEIN, HUMAN; CYTIDINE DEAMINASE; MINOR HISTOCOMPATIBILITY ANTIGEN; OXIDOREDUCTASE; TP53 PROTEIN, HUMAN; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; WWOX PROTEIN, HUMAN;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER TISSUE; CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; DNA DAMAGE; ENZYME SUBSTRATE COMPLEX; GENE SILENCING; GENETIC ANALYSIS; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LUNG ADENOCARCINOMA; MOUSE; MUTAGENESIS; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; SOMATIC HYPERMUTATION; TP53 GENE; ADENOCARCINOMA; CELL LINE; CELL TRANSFORMATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; PATHOLOGY;

ACID ANHYDRIDE HYDROLASES; ADENOCARCINOMA; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CYTIDINE DEAMINASE; DATABASES, GENETIC; DNA DAMAGE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MINOR HISTOCOMPATIBILITY ANTIGENS; MUTAGENESIS; MUTATION; NEOPLASM PROTEINS; OXIDOREDUCTASES; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84923306447     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2636     Document Type: Article

References (37)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
2. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 1991; 51:3075-3079.
3. Nik-Zainal S, Alexandrov LB, Wedge DC, Loo PV, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, Menzies A, Martin S, Leung K, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012; 149:979-993.
4. Stephens P, Edkins S, Davies H, Greenman C, Cox C, Hunter C, Bignell G, Teague J, Smith R, Stevens C, O'Meara S, Parker A, Tarpey P, et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet. 2005; 37:590-592.
5. Drier Y, Lawrence MS, Carter SL, Stewart C, Gabriel SB, Lander ES, Meyerson M, Beroukhim R, Getz G. Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res. 2013; 23:228-235.
6. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale A, Boyault S, Burkhardt B, Butler AP, et al. Signatures of mutational processes in human cancer. Nature. 2013; 500:415-421.
7. Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K, Campbell PJ, Rada C, Stratton MR, Neuberger MS. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. Elife. 2013; 16:e00534.
8. Lada AG, Dhar A, Boissy R, Hirano M, Rubel A, Rogozin TB, Pavlov YI. AID/APOBEC cytosine deaminase induces genome-wide kataegis. Biol Direct. 2012; 7:47.
9. Smith HC, Bennett RP, Kizilyer A, McDougall WM, Prohaska KM. Functions and regulation of the APOBEC family of proteins. Semin Cell Dev Biol. 2012; 23:258-268.
10. Beale RC, Peterson-Mahrt SK, Watt IN, Harris RS Rada C, Neuberger MS. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J Mol Biol. 2012; 337:585-596.
11. Chelico L, Pham P, Goodman MF. Mechanisms of APOBEC3G-catalyzed processive deamination of deoxycytidine on single-stranded DNA. Nat Struct Mol Biol. 2009; 16:454-455, author reply 455-456.
12. Poltrovastsky V, Heacock M, Kissling GE, Prasad R, Wilson SH. Mutagenesis depdendent upon the combination of activation-induced deaminase expression and double-strand break. Mol Immunol. 2010; 48:164-170.
13. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz NA, Donohue DE, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature. 2013; 494:366-370.
14. Roberts SA, Lawrence MS, Klimczak LJ, Grim SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, Harris S, Shah RR, Resnick MA, et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 2013; 45:970-976.
15. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet. 2013; 45:977-983.
16. Sasaki H, Suzuki A, Tatematsu T, Shitara M, Hikosaka Y, Okuda K, Moriyama S, Yano M, Fujii Y. APOBEC3B gene overexpression in non-small-cell lung cancer. Biomed Rep. 2014; 2:392-395.
17. Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, Vogel RI, Nikas JB, Law EK, Brown WL, Li Y, Zhang Y, Maurer MJ, et al. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 2013; 73:222-231.
18. Nik-Zainal S, Wedge DC, Alexandrov LB, Petljak M, Butler AP, Bolli N, Davies HR, Knappskog S, Martin S, Papaemmanuli E, Ramakrishna M, Shlien A, Simonic I, et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat Genet. 2014; 46:487-491.
19. Cimprich KA, Cortez D. ATR: essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008; 9:616-27.
20. Jazayeri A, Falck J, Lukas C, Bartek J, Smith G, Lucas J, Jackson SP. ATM-and cell cycle-dependent regulation of ATR in response to DNA double strand breaks. Nat Cell Biol. 2006; 8:37-45.
21. Di Fagagna FA. Living on a break: cellular senescenceas a DNA-damage response. Nat Rev Cancer.2008; 8:512-522.
22. Wang JYJ. DNA damage and apoptosis. Nature. 2011; 8:1047-1048.
23. Saldivar JC, Miuma S, Bene J, Hosseini SA, Shibata H, Sun J, Wheeler LJ, Matthews CK, Huebner K. Initiation of genome instability and preneoplastic process through loss of Fhit expression. PLoS Genet. 2012; 8:e1003077.
24. Saldivar JC, Shibata H, Huebner K. Pathology and biology associated with the fragile FHIT gene and gene product. J Cell Biochem. 2013; 109:858-865.
25. Miuma S, Saldivar JC, Karras JR, Waters CE, Paisie CA, Wang Y, Jin V, Sun J, Druck T, Zhang J, Huebner K. Fhit deficiency-induced global genome instability promotes selective mutation and clonal expansion. PLoS ONE. 2013; 8:e80730.
26. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Chirelli C, Tornielli S, Sard L, Huebner K, Pierotti MA, Croce CM, Pilotti S. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 1998; 58:5032-5037.
27. Cirombella R, Montrone G, Stoppacciaro A, Giglio S, Volinia S, Graziano P, Huebner K, Vecchione A. Fhit loss in lung preneoplasia: relation to DNA damage response checkpoint activation. Cancer Lett. 2010; 291:230-236.
28. Guler G, Uner A, Guler N, Han SY, Illiopoulos D, McCue P, Huebner K. Concordant loss of fragile gene expression early in breast cancer development. Pathol Int. 2005; 55:471-478.
29. Terry G, Ho L, Londesborough P, Duggan C, Hanby A, Cuzick J. The expression of FHIT, PCNA, and EGFR in benign and malignant breast lesions. Br J Cancer. 2007; 96:110-117.
30. Fong LY, Fidanza V, Zanesi N, Lock LF, Siracusa LD, Mancini R, Siprashvili Z, Ottey M, Martin SE, Druck T, McCue PA, Croce CM, Huebner K. Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci USA. 2000; 97:4742-4747.
31. Guler G, Himmetoglu C, Jimenez RE, Geyer SM, Wang WP, Costinean S, Pilarski RT, Morrison C, Suren D, Liu J, Chen J, Kamal J, Shapiro CL, et al. Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. Breast Cancer Res Treat. 2011; 129:421-432.
32. Shinohara M, Io K, Shindo K, Matsui M, Sakamoto T, Tada K, Kobayashi M, Kadowaki N, Takaori-Kondo A. APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci Rep. 2012; 2:806.
33. Simonelli V, Narciso L, Dogliotti E, Fortini P. Base excision repair intermediates are mutagenic in mammalian cells. Nucleic Acids Res. 2005; 33:4404-4411.
34. Chen J, Miller BF, Furano AV. Repair of naturall occurring mismatches can induce mutations in flanking DNA. eLife. 2014; 3:eo2001. Doi: 10.7554/eLife.02001.
35. Crooks GE, Hon G, Chandonia JM, Brenner SE. WebLogo: A sequence logo generator. Genome Res. 2004; 14: 1188-1190.
36. Druck T, Hadaczek P, Fu TB, Ohta M, Siprashvili Z, Baffa R, Negrini M, Kastury K, Veronese ML, Rosen D, Rothstein J, McCue P, Cotticelli MG, et al. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res. 1997; 57:504-512.
37. Suspene R, Caval V, Henry M, Bouzidi MS, Wain-Hobson S, Vartanian JP. Erroneous indentification of APOBEC3-edited chromosomal DNA in cancer genomics. Br J Cancer. 2014; 110:2615-2622.